Skip to main content
ADIL logo

ADIL · Adial Pharmaceuticals, Inc.

$3.34 +0.05 (+1.52%) At close · Jul 31
Market Cap
$7.16M
Shares
2.14M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2024
Executive Total
Cary Claiborne $976,339
Tony Goodman $376,198
Joseph A. M. Truluck $328,415
Fiscal 2023
Executive Total
Cary Claiborne $801,621
Bankole A. Johnson $435,000
Joseph A. M. Truluck $389,033
Tony Goodman $258,932
Fiscal 2022
Executive Total
Cary Claiborne $1,196,988
William B. Stilley $591,576
Joseph A. M. Truluck $510,540
Bankole A. Johnson $489,422
Fiscal 2021
Executive Total
William B. Stilley $1,227,856
Joseph A. M. Truluck $624,524
Cary Claiborne $466,763
Fiscal 2020
Executive Total
William B. Stilley $1,133,903
Joseph A. M. Truluck $451,033
Bankole A. Johnson $375,000
Cary Claiborne
Fiscal 2019
Executive Total
William B. Stilley $2,366,387
Bankole A. Johnson $1,109,580
Joseph A. M. Truluck $727,074
Fiscal 2018
Executive Total
William B. Stilley $1,211,656
Joseph A. M. Truluck $308,363

Executive changes

Person Change Filed
James W. Newman, Jr. Resigned 2026-01-06
Key facts CIK 1513525 CUSIP 00688A304 13F (30d) 29 filings 4 filers Visit website Investor relations